Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.


Before the introduction of bisphosphonates (BPs), patients with malignant bone disease could expect to experience multiple skeletal-related events (SREs) during the last few months of life, including pathologic fracture, spinal cord compression, and hypercalcemia of malignancy. These serious and potentially debilitating events not only diminished patients… (More)
DOI: 10.1016/S1040-8428(11)00032-1


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.